Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ear Diseases, NF2-related schwannomatosis, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, acoustic neuroma, cranial nerve neoplasm, cranial nerve neuropathy, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neuroendocrine neoplasm, neurofibroma, neurofibromatosis, neuroma, otorhinolaryngologic disease, primitive neuroectodermal tumor, retrocochlear disease, schwannoma, vestibulocochlear nerve disorder	Not yet recruiting	Phase 1 / Phase 2	2026-01-23		NCT07131722

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
PRG Science & Technology Co., Ltd.	3

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.